A best evidence topic was written according to a structured protocol. The question addressed was whether patients undergoing coronary bypass grafting and mitral intervention for moderate to severe ischaemic mitral regurgitation are best treated with mitral repair or replacement. Five hundred and fifty papers were found using the reported search. Based on the 14 non-randomised studies judged to represent best evidence, we concluded that whilst there is some evidence that the operative mortality may be less following mitral valve repair, long-term data are equivocal. Even with contemporary techniques, recurrent mitral regurgitation is not uncommon following repair. Replacement was more frequently performed for patients with greater co-morbidity. Whilst two studies attempted to control for this using propensity analysis, in the majority of studies this introduced considerable bias. No data was available on long-term functional outcomes and quality of life. As there is currently insufficient evidence to inform clinical practice, a randomised trial is warranted in this important area.
Introduction
A best evidence topic was constructed according to a structured protocol w1x.
Clinical scenario
A patient is referred with dyspnoea and angina. Angiography shows severe triple vessel disease. Echocardiography shows restricted posterior mitral valve leaflet motion with moderate regurgitation. Ventricular function is mildly impaired. The referring cardiologist suggests concomitant mitral surgery because of the adverse prognosis of residual mitral regurgitation (MR) following coronary artery bypass grafting (CABG) in this patient group w2x. The surgeons present disagree whether it is better to repair or replace the mitral valve.
Three-part question
In wpatients undergoing mitral surgery for Ischemic Mitral Regurgitation (IMR)x is it preferable to wrepair or replace the mitral valvex in terms of woperative mortality, re- operation rate, echocardiographic, functional outcomes and long-term survivalx
Search strategy
Medline search from January 1947 to May 2010 was performed using the OVID interface: (exp Mitral Valve Insufficiencyyor exp Mitral Valve Prolapsey) and (exp Ischemiay or exp Myocardial Ischemiay) and (replacement or repair). mp. LIMIT to human studies. American Heart Association (AHA) and National Institute for Health and Clinical Excellence (NICE) guidelines were also searched.
Search outcome
Five hundred and fifty papers were found of which 15 were deemed to be represent best evidence (Table 1) .
Results
The Joint American Heart AssociationyAmerican College of Cardiology guidelines w3x omit important references and do not discuss the option of replacement.
The 14 comparative case series identified also have significant limitations, but offer an insight into variations in surgical practice and outcomes w4-17x. No study routinely used preoperative transoesophageal echocardiography, exercise echocardiography or cardiac magnetic resonance imaging to assess the pathology or severity. The studies often include patients operated on prior to the popularisation of downsizing annuloplasty as the repair technique of choice w18x. Many studies do not adequately describe the techniques used, or report sub-optimal techniques such as incomplete rings, inadequate downsizing. Many include additional leaflet or chordal procedures and obsolete procedures such as pericardial annuloplasty. Similarly, when the mitral valve is replaced, the degree of preservation of the subvalvular apparatus is often not reported or sub-optimal w19x.
Thirty-day mortality is generally less for repair than replacement; however this was not consistent in all studies and may be explained by the sickest patients having replacements.
The two studies that used propensity matching found no difference, after correcting for co-morbidity w4, 14x.
Both procedures were associated with poor survival with little difference between groups. Some studies report no difference in survival w7, 15x, some report better survival with repair w4, 6, 8, 9, 13x, while others favour replacement w5, 11, 16, 17x. Four studies fail to report the severity of IMR and so risk, including patients with mild IMR who have little to benefit from intervention w4, 5, 8, 10x. Reoperation rate is variably reported, but generally higher in the repair group w8, 16, 17x.
Many studies observed that co-morbidity rather than procedure is also the strongest predictor of late outcomes w4, 6, 11, 13x. Significantly the replacement group had a larger proportion of acute cases with greater levels of co-morbidity in many studies w5, 9, 12, 14x.
There is significant selection bias towards repair as it is frequently used in annular dilation, while replacement is used in restricted leaflet motion and papillary dysfunction w8, 11x, the latter not being classically regarded as chronic IMR. The reporting of failed intraoperative repairs converted to replacement as part of the replacement group is also a cause of bias w5-8, 12, 15-17x.
Operative mortality, reoperation rate and survival are unreliable indicators of procedural success in this patient group. More pertinent outcomes measures would include late echocardiography w20x, to demonstrate durable repair, and functional outcomes, to demonstrate patient benefit. Unfortunately, unlike for non-ischaemic mitral regurgitation this data is not reported w20x. Functional outcomes, assessed predominantly using dyspnoea and angina scores, were either not reported separately for repair and replacement w5, 7x, or showed no difference w9, 12x. Late echocardiographic freedom from greater than mild MR varied from 50 to 85% w4, 9, 11, 13x, highlighting the variability in the efficacy and durability of repair.
Clinical bottom line
Current guidelines are inadequate to inform clinical practice. Overall, mortality for CABG plus mitral valve repair in the 14 published comparative studies is lower than CABG with mitral valve replacement. However, this finding was not consistent throughout the studies, with several showing higher mortality with repair. This discrepancy is likely to be due to heterogeneous study populations. Further problems with these studies are the widespread application of sub-optimal repair and replacement techniques, often in historical cohorts; the inclusion of acute cases and variations in data reporting (in terms of intention to treat analysis). Few papers present functional or late echocardiographical outcomes.
A randomised trial is clearly warranted w4, 5, 14x. Power calculation depends on the primary end point (mortality or functional outcome) suggesting that patients should be recruited with moderate to severe IMR on preoperative transoesophageal echo, confirmed by exercise testing and randomised to revascularisation combined with either systematically applied downsizing, complete ring, annuloplasty, or complete subvalvular sparing mitral valve replacement, preferably with bioprosthesis. The durability of repair should be documented at early and late time points. To reduce cost and number of patients (approx. 100) primary outcomes should be functional (e.g. oxygen consumption-MV02). Secondary outcomes should include survival and freedom from more than mild MR.
